Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Venous Thromboembolism 10Pulmonary Embolism 4Venous Thrombosis 3Neoplasms 3Thrombosis 2Multiple Myeloma 2Urinary Bladder Neoplasms 1Thromboprophylaxis 1Thromboembolism 1Thrombocytopenia 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Fibrosis 1Embolism 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

apixaban 4abelacimab 2MAA868 2isoquercitrin 1enoxaparin sodium 1Rosuvastatin Calcium 1Rivaroxaban 1Heparin, Low-Molecular-Weight 1Enoxaparin 1Educational Status 1Dalteparin 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pulmonary Embolism × apixaban × 1 year × Clear all
NCT07493304 2026-05-29

ROXI-CAT-II

Regeneron Pharmaceuticals

Phase 3 Recruiting
1,600 enrolled
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT06886516 2026-04-15

Apixaban in Thrombocytopenia

Beth Israel Deaconess Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Classical hematology

Pulmonary Embolism, Thrombocytopenia, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

NCT05171049 2026-02-23

ASTER

Anthos Therapeutics, Inc.

Phase 3 Terminated
1,150 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT07270263 2025-12-26

HEM-DOAC

Medical University of Gdansk

Phase NA Recruiting
100 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Pulmonary Embolism, Hematologic Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡